Dr Mozayeni brings deep experience in biotech corporate strategy and business development Appointment follows successful £35 million Series A fundraise at the end of 2024 to take its MSH3 inhibitors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback